REGN Stock Recent News

Regeneron Pharmaceuticals, Inc.

The bear market induced by the Federal Reserve's monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector.

Regeneron Pharmaceuticals gets a buy rating today, agreeing with the Wall St consensus. Impressive are its drug discovery pipeline across several clinical segments, profit margins, and low Debt/Equity ratio. The firm just started paying dividends in February, so still lacks dividend growth data long-term.

President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.

LOS ANGELES, May 2, 2025 /PRNewswire/ -- Landmark Science, a premier provider of real-world evidence (RWE) solutions, is redefining industry standards with its white-glove, high-touch approach to evidence generation. With long-standing roots in biopharma, Landmark Science bridges the gap between vendors and biopharma, delivering agile and efficient solutions uniquely tailored to clients. This hand-held approach through and through helps clients avoid typical red tape situations that can delay or halt critical evidence generation to swiftly transform evidence into insights on patient care, access, and outcomes. Landmark Science founder and CEO, Shivani Aggarwal, PhD, MS, brings 15 years of experience in RWE and clinical trials from her time at leading life science companies Amgen, Regeneron, and IQVIA. With deep scientific acumen and a strong track record in evidence generation, Shivani Aggarwal drives Landmark Science's strategic vision, spearheading the delivery of innovative, data-dr

18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies 18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies

24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma

On Tuesday, Regeneron Pharmaceuticals Inc REGN  reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82.

REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Ryan Crowe - SVP, IR Leonard Schleifer - Board Co-Chair, Co-Founder, President and CEO George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - EVP, Commercial Chris Fenimore - EVP and CFO Conference Call Participants Tyler Van Buren - TD Cowen Alexandria Hammond - Wolfe Research Chris Schott - JPMorgan Terence Flynn - Morgan Stanley Akash Tewari - Jefferies Carter Gould - Cantor William Pickering - Bernstein Evan Seigerman - BMO Capital Markets Salveen Richter - Goldman Sachs David Risinger - Leerink Partners Operator Welcome to the Regeneron Pharmaceuticals' First Quarter 2025 Earnings Conference Call. My name is Josh, and I will be your operator for today's call.